Leveraging TRPV1 for intracellular delivery of membrane impermeant compounds in the brain
Authors:
Open Access
- 12 December 2025
- journal article
- research article
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Abstract
Large-pore ion channels present a window of opportunity for cell-specific intracellular drug delivery. Here, we demonstrate that the capsaicin receptor, TRPV1, can be used for delivery of the membrane impermeant lidocaine derivative QX-314 into neurons in the brain in vivo by using drug-induced hyperlocomotion as a behavioral readout and we validated our findings with ex vivo electrophysiological recordings. Our studies present evidence that this strategy can be used to deliver membrane impermeant compounds in the brain.Keywords
Funding Information
- National Science Foundation (NSF GRFP 1937963)
- National Institute on Drug Abuse (R01 DA040630)
This publication has 25 references indexed in Scilit:
- Why 90% of clinical drug development fails and how to improve it?Acta Pharmaceutica Sinica B, 2022
- Patch-clamp and multi-electrode array electrophysiological analysis in acute mouse brain slicesSTAR Protocols, 2021
- Targeting Strategies for Tissue-Specific Drug DeliveryCell, 2020
- A Motivational and Neuropeptidergic Hub: Anatomical and Functional Diversity within the Nucleus Accumbens ShellNeuron, 2019
- Differential cytotoxicity and intracellular calcium-signalling following activation of the calcium-permeable ion channels TRPV1 and TRPA1Cell Calcium, 2017
- Conditioned cues and the expression of stimulant sensitization in animals and humansNeuropharmacology, 2009
- The locomotor effects of MK801 in the nucleus accumbens of developing and adult ratsEuropean Journal of Pharmacology, 1999
- The behavioral effects of MK-801 injected into nucleus accumbens and caudate-putamen of ratsPharmacology Biochemistry and Behavior, 1995
- Effects of dopamine D1 and D2 receptor blockade on MK-801-induced hyperlocomotion in ratsPsychopharmacology, 1993
- The behavioural effects of MK-801: a comparison with antagonists acting non-competitively and competitively at the NMDA receptorEuropean Journal of Pharmacology, 1989